P. Krogsgaard-Larsen, S. B. Christensen, H. Kofod (Eds.) (1984). Natural Products and Drug
Development. Copenhagen: Munksgaard.
E. S. Lander, R. A. Weinberg (2000). Genomics: journey to the center of biology. Science 287:
1777–1782.
K. Pal (2000). The keys to chemical genomics. Mod. Drug Discov. 3: 46–58.
P. J. Rosenthal (2003). Antimalarial drug discovery: old and new approaches. J. Exp. Biol. 206 :
3735–3744.
A. M. Rouhi (2003). Pharmaceuticals: rediscovering natural products. Chem. Eng. News 41:
77–90.
P. A. Singer, A. Daar (2001). Harnessing genomics and biotechnology. Science. 294: 87–89.
N. Sleep (2000). Sorting out combinatorial chaos. Mod. Drug Discov. 3: 37–46.
N. J. de Souza, B. N. Ganguli, J. Reden (1982). Strategies in the discovery of drugs from natural
sources.Annu. Rep.Med. Chem. 17: 301–310.
J. J. Stezowski, K. Chandrasekhar (1986). X-ray crystallography of drug molecule–macromolecule
interactions as an aid to drug design. Annu. Rep. Med. Chem. 21: 293–302.
E. A. Swinyard (1980). History of the Antiepileptic Drugs. In: G. Glaser, J. Penry, D. Woodbury
(Eds.).Antiepileptic Drugs: Mechanism of Action. New York: Raven Press. p. 1.
A. S. Verkman (2004). Drug discovery in academia. Am. J. Physiol. 286 : C465–C474.
Synthesis of a Lead Compound
M. A. Fox, J. K. Whitesell (2004). Organic Chemistry3rd ed. Toronto: Jones and Bartlett, (excel-
lent description of syntheses of diazepam, ibuprofen, sertraline).
N. J. Hrib (1986). Recent development in computer-assisted organic synthesis. Annu. Rep. Med.
Chem. 21: 303–311.
J. MacCoss, T. Baillie (2004). Organic chemistry in drug discovery. Science 303: 1810–1813.
S. L. Schreiber (2000). Target-oriented and diversity-oriented organic synthesis in drug discovery.
Science 287: 1964–1969.
Optimizing a Lead Compound
T. M. Allen, P. R. Cullis (2004). Drug delivery systems: entering the mainstream. Science 303:
1818–1821.
S. C. Basak, D. K. Harris, V. R. Magnuson (1984). Comparative study of lipophilicity versus
topological molecular descriptors in biological correlations. J.Pharm. Sci. 73 : 429–437.
N. Bodor (1982). Soft drugs: strategies for design of safer drugs. In: J. A. Keverling–Buisman
(Ed.).Strategy in Drug Design. Amsterdam: Elsevier.
N. Bodor (1984). Novel approaches to the design of safer drugs: soft drugs and site–specific
delivery systems. In: B. Testa (Ed.). Advanced Drug Research, vol. 13. New York: Academic
Press, pp. 255–331.
D. E. Clark (2003). In silicoprediction of blood–brain barrier permeation. Drug Discov. Today 8:
927–933.
P. V. Desai, E. C. Coutinho (2001). QSAR in drug discovery and development. Asian Chem. Lett.
5 : 77–86.
O. Dror, A. Shulman-Peleg, R. Nussinov, H. J. Wolfson (2004). Predicting molecular interactions
in silico: I. A guide to pharmacophore identification and its applications to drug design.
Curr. Med. Chem. 11: 71–90.
N. L. Henderson (1983). Recent advances in drug delivery system technology. Annu. Rep. Med.
Chem. 18: 275–284.
164 MEDICINAL CHEMISTRY